The 503B Bulks List Proposed Rule, Annotated
On April 30, 2026 the FDA moved to strip semaglutide, tirzepatide, and liraglutide of the regulatory status that made mass compounding lawful. This is what the proposal does, which statutory hooks it uses, and which questions it leaves open.
Findings
- On April 30, 2026 the FDA said it wants to end most compounding of semaglutide, tirzepatide, and liraglutide, on a finding that there is no longer a clinical need for certain compounded versions.
- The mechanism removes both the bulks-list pathway and the shortage-list pathway for these three molecules.
- The proposal targets 503B outsourcing facilities compounding from bulk drug substance. Patient-specific 503A compounding sits on separate statutory footing.
- The FDA's stated rationale rests on a clinical-need determination, which is the finding any legal challenge will attack.
Filing at a glance
The two doors, and why both are being shut
Large-scale compounding of a commercially available drug requires a legal justification. Between 2022 and 2025 that justification was shortage status: federal law permits compounding of drugs appearing on the FDA's shortage list. When the agency declared the GLP-1 shortages resolved, that door closed.
A second door stayed open. Bulk drug substances that appear on the 503B Bulks List may be compounded by registered outsourcing facilities without reference to shortage status. That list is a separate administrative instrument, and it is the one the April 30 proposal targets. The agency's position is that outsourcing facilities have no remaining clinical need to compound these three drugs from scratch.
A substance earns a bulks-list position because compounding it serves a clinical need that approved products do not meet. Everything in this proposal rests on the determination that the need has lapsed. Not on patent, not on safety findings, not on enforcement discretion — on clinical need. Any legal challenge will be aimed there.
What changed in the factual record between 2022 and 2026
The clinical-need argument is easier for the agency to make now than it was two years ago, and the reason is supply and format availability rather than any change in law:
- 2022Semaglutide and tirzepatide enter shortage; compounding expands under shortage-list eligibility.
- Late 2024–2025FDA declares the shortages resolved. Wind-down deadlines follow for 503A and 503B facilities.
- December 2025FDA approves oral semaglutide — the Wegovy pill. Novo Nordisk launches it in January 2026.
- April 1, 2026FDA approves Foundayo (orforglipron), the first GLP-1 pill with no food or water timing restrictions.
- April 30, 2026FDA proposes removing semaglutide, tirzepatide, and liraglutide from the 503B Bulks List.
The sequence matters. An argument that patients need a compounded oral formulation because no approved oral product exists was defensible in 2024. With two approved oral GLP-1s on the market, it is not.
The additive question the proposal has to answer
The compounding industry's principal response to the end of shortage eligibility was reformulation. IQVIA reported that more than 80% of compounded semaglutide and tirzepatide prescriptions included supplemental ingredients such as B vitamins including B6, B12, and B3, or levocarnitine. The IQVIA researchers wrote that these additives may serve as a rationale for continued compounding despite the FDA's resolution of supply shortages, and that some compounders may be using the modifications to differentiate their products or navigate regulatory ambiguity.
The FDA has been consistent in rejecting the additive argument as a standalone justification: a documented medical necessity for a specific patient is required, and adding an ingredient does not by itself create one. In warning letters to telehealth companies in February 2026 the agency addressed a related marketing problem, objecting to claims that implied compounded products had been FDA-approved or evaluated for safety and effectiveness when they had not.
Coverage of the proposal has noted it may leave room for medical spas and some telehealth companies that have continued to sell compounded GLP-1s with additives. The rule addresses 503B bulk compounding. Patient-specific compounding under a documented medical necessity is a different statutory provision and is not eliminated by this action.
- Whether the rule will be finalised in its proposed form, or narrowed in response to comment.
- What compliance or wind-down period finalisation would carry.
- How aggressively the agency intends to police patient-specific 503A compounding once the 503B route closes.
- Whether a legal challenge to the clinical-need determination succeeds, and on what administrative-law grounds.
The parallel pressure: private litigation
Rulemaking is not the only force narrowing this market, and it may not be the fastest. Novo Nordisk sued Hims & Hers for patent infringement in February 2026 and has said it has now filed 132 suits across 40 states, winning 44 permanent injunctions. Eli Lilly sued the compounders Strive Pharmacy and Empower in April 2025, followed by four telehealth companies weeks later.
Distribution has moved ahead of the regulation. Hims & Hers announced in March 2026 it would make Novo Nordisk's semaglutide injections and pills available to subscribers while continuing to offer compounded GLP-1s where a provider determines one is clinically necessary. Ro struck a deal with Eli Lilly in April 2026 to prescribe Foundayo, and also offers semaglutide pills and injections and tirzepatide injections.
What we will be watching
The comment docket is where the substantive argument happens. The compounding industry's strongest available position is not that shortages persist — that ship has sailed — but that clinical need is not coextensive with commercial availability, and that specific patient populations remain underserved by approved formulations. Whether the agency's record adequately addresses that argument is the question that determines whether this rule survives review.
Primary sources & citations
- US Food and Drug Administration, proposed action on 503B Bulks List status for semaglutide, tirzepatide, and liraglutide, announced April 30, 2026.
- Medscape, “FDA Proposes End to Mass GLP-1 Compounding,” May 1, 2026.
- Pharmacy Times, reporting on the proposed rule barring 503B bulk compounding of GLP-1 receptor agonists.
- IQVIA, analysis of supplemental ingredients in compounded semaglutide and tirzepatide prescriptions, October report on fall 2025 data.
- US Food and Drug Administration warning letters to telehealth companies, February 2026.
- FDA press announcement on approval of Foundayo (orforglipron), April 1, 2026.
- Federal Food, Drug, and Cosmetic Act, sections 503A and 503B.
Editorial note
Looking for a provider rather than a citation?
This site does not review or rank telehealth providers inside its research articles, and carries no provider links in article text. Our provider comparison grid, including how each one is monetized, lives on the homepage.
Open the provider grid